To investigate how gene editing can mitigate the pathology of AHC in vivo, we engineered PE strategies to efficiently correct the mouse Atp1a3 D801N and E815K mutations—orthologous to the two most prevalent human pathogenic variants—in two AHC mouse models. This evidence concerns the gene ATP1A3 and alternating hemiplegia of childhood.